220
Participants
Start Date
July 2, 2025
Primary Completion Date
July 31, 2027
Study Completion Date
July 31, 2027
YL217
Patients will be treated with YL217 intravenous(IV)infusion.
YL217
Patients will be treated with YL217 intravenous(IV)infusion.
YL217
Patients will be treated with YL217 intravenous(IV)infusion.
NOT_YET_RECRUITING
Columbia University Irving Medical Center, New York
NOT_YET_RECRUITING
Cleveland Clinic Taussig Cancer Institute, Cleveland
NOT_YET_RECRUITING
Karmanos Cancer Institute, Detroit
NOT_YET_RECRUITING
University of Wisconsin Health - UW Carbone Cancer Center, Madison
NOT_YET_RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
UT Health San Antonio - Mays Cancer Center, San Antonio
NOT_YET_RECRUITING
UCLA Hematology/Oncology - Santa Monica, Santa Monica
RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
Yale Cancer Center, New Haven
NOT_YET_RECRUITING
Massachusetts General Hospital, Boston
MediLink Therapeutics (Suzhou) Co., Ltd.
INDUSTRY